Which Providers in the Evanston and Chicago Area Offer Deep TMS for OCD?

Direct Answer

Look for a service that runs the OCD protocol rather than adapting its depression protocol, since the two are materially different. The OCD protocol uses a different coil, targets different structures and includes a brief individualized symptom provocation before each session. Ask the service directly whether it delivers OCD-specific treatment, which coil it uses and who conducts the provocation, because a clinic that treats depression with transcranial magnetic stimulation does not automatically treat OCD.

Two things are worth settling before the referral. First, confirm that prior treatment was adequate by OCD standards rather than depression standards, since OCD generally requires higher doses and longer trials. Second, expect coverage friction. Deep TMS holds an FDA clearance for OCD, and coverage policy is written separately, so verify funding rather than assuming that clearance implies payment.

The OCD Protocol Is Not the Depression Protocol

This is the point most referring clinicians have not been told. In the pivotal trial, deep TMS for OCD used the H7 coil, designed to target the medial prefrontal cortex and anterior cingulate cortex, rather than the coil and dorsolateral prefrontal target used for depression.¹ The anatomical target reflects a different model of the disorder, not a different setting on the same machine.

The protocol also includes a step that has no equivalent in depression treatment. Each session was preceded by a three to five minute individualized symptom provocation intended to activate the relevant circuit, with the patient held at a distress rating between four and seven on a visual analogue scale before stimulation began.¹ Treatment ran daily for six weeks.¹

That provocation step has practical consequences a referrer should raise in advance. It requires the clinician to know the client’s specific obsessional content and it is briefly distressing by design. It also means the person delivering treatment needs genuine familiarity with OCD rather than a general TMS background. A client who expects a passive procedure and encounters deliberate symptom activation may disengage in the first week.

What the Pivotal Trial Showed

The multicenter randomized double-blind sham-controlled trial enrolled 99 patients with treatment-resistant OCD across 11 centers. Response was defined as a reduction of at least 30 percent on the Yale-Brown Obsessive Compulsive Scale. At the end of treatment, 38.1 percent of the active group responded compared with 11.1 percent of the sham group. At one-month follow-up the figures were 45.2 percent and 17.8 percent.¹

Those numbers support an honest framing rather than an enthusiastic one. Roughly two in five treatment-resistant patients responded, against roughly one in nine on sham, and response meant a meaningful reduction in symptoms rather than remission. That is a real effect in a population that has already failed standard treatment, and it is not a cure. Clients who arrive expecting resolution will be disappointed by an outcome that the field considers a success.

Adequacy Is the Question to Settle First

A substantial share of OCD referrals labeled treatment-resistant have an adequacy problem rather than a resistance problem, and the standards differ from those for depression. The International OCD Foundation notes that SSRI doses up to two to three times higher than those typically used for depression and anxiety produce the greatest benefit in OCD, and that an adequate trial runs eight to 12 weeks with at least six of those weeks at moderate to high doses.² It also cautions that inadequate dosing or duration frequently leads to unnecessary medication switches.²

Apply that standard to the history before referring. A client who reached 50 milligrams of sertraline for six weeks has not had an adequate OCD trial by this benchmark, whatever the chart says. The same logic applies to psychotherapy. Exposure and response prevention is the established psychotherapy for OCD, and a client who has had supportive counseling, or exposure work delivered without a structured response-prevention component, has not had an adequate trial of it either. Establishing both before referring makes the consultation more useful and occasionally makes it unnecessary.

Clearance and Coverage Diverge Here More Than Anywhere Else

BrainsWay states that its Deep TMS system has been FDA-cleared for obsessive compulsive disorder since 2018.³ The Medicare local coverage determination for transcranial magnetic stimulation in adults with major depressive disorder states that treatment for conditions other than severe major depressive disorder, specifically including obsessive compulsive disorder, is not medically reasonable and necessary under that policy.⁴

For an OCD referral specifically, treat funding as an open question from the outset. Ask the service what it typically sees from commercial plans for this indication, whether it pursues single case agreements and what self-pay costs. Yellowbrick provides neuroscience technologies and neuromodulation services through an agreement with its sister company Synchrony Brain Health, which delivers Deep TMS on an outpatient basis, and coverage pathways for an OCD course should be confirmed with the service before a client is told the treatment is available to them.

What to Verify for an OCD Referral Specifically

What to Prepare and What to Tell the Client

• A medication table showing each SSRI trial with peak dose, weeks at that dose and reason for discontinuation, measured against OCD dosing standards.
• A psychotherapy history stating explicitly whether exposure and response prevention was delivered and by whom.
• The current Yale-Brown Obsessive Compulsive Scale score if available, since it is the standard outcome measure.
• The client’s specific obsessional content, with their consent, since provocation depends on it.
• Tell the client the protocol includes brief deliberate symptom provocation before each session.
• Tell the client the course runs daily on weekdays for approximately six weeks.
• Give an honest response figure rather than a general reassurance, and define what response means.
• Confirm that you intend to continue exposure work alongside the course, if that is the plan.
• Establish the coverage or self-pay position before the first appointment.
• Arrange for the service to report back to you, with a release in place.

Key Takeaway

Ask whether a service runs the OCD protocol rather than whether it offers TMS, because the OCD course uses a different coil, a different anatomical target and an individualized symptom provocation before every session. Settle adequacy first, using OCD standards of eight to 12 weeks with at least six weeks at moderate to high dose, and check whether exposure and response prevention was genuinely delivered rather than merely attempted. Give clients accurate expectations: in the pivotal trial 38.1 percent of active patients responded at end of treatment compared with 11.1 percent on sham, where response meant at least a 30 percent reduction in symptoms rather than remission. Then treat coverage as an open question, since deep TMS has been cleared for OCD since 2018 while coverage policy is written separately and frequently excludes it.

Clinical Note

This article is general guidance for referring clinicians. It is not a substitute for individual clinical judgment or an individualized assessment, it does not establish candidacy for any procedure and it does not constitute medical, coverage or benefits advice. Candidacy, protocol selection and device selection rest with the treating physician and the treating service. Safety screening and contraindications are assessed separately by the service. Trial results describe study populations and do not predict outcomes for any individual patient. FDA clearances and coverage policies vary and change, so confirm both directly.

If a client is in immediate danger, direct them to emergency services. The 988 Suicide and Crisis Lifeline provides free, confidential crisis support 24 hours a day, seven days a week, by call or text to 988.⁵

Glossary

• H7 coil: the deep TMS coil used in the OCD protocol, designed to target the medial prefrontal cortex and anterior cingulate cortex.
• Symptom provocation: a brief individualized procedure performed before each OCD stimulation session to activate the relevant circuit, calibrated to a target distress level.
• Yale-Brown Obsessive Compulsive Scale (YBOCS): the standard clinician-administered measure of OCD symptom severity.
• Response: in the pivotal deep TMS trial, a reduction of at least 30 percent in YBOCS score, which is distinct from remission.
• Exposure and response prevention (ERP): the established behavioral psychotherapy for OCD, combining graded exposure with prevention of the compulsive response.
• Adequate SSRI trial in OCD: commonly defined as eight to 12 weeks with at least six weeks at moderate to high dose, higher than the standard used in depression.
• Treatment-resistant OCD: OCD that has not responded to adequate trials of first-line treatment, where adequacy is judged by OCD-specific standards.

References

1. Carmi L, Tendler A, Bystritsky A, et al. “Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial.” American Journal of Psychiatry, 2019. Accessed August 25, 2026. https://psychiatryonline.org/doi/10.1176/appi.ajp.2019.18101180.
2. International OCD Foundation. “Medication.” OCD Treatment Guide. Accessed August 25, 2026. https://iocdf.org/medication/.
3. BrainsWay. “Which conditions is Deep TMS officially cleared to treat?” BrainsWay professionals FAQ. Accessed August 25, 2026. https://www.brainsway.com/professionals-faqs/what-mental-health-conditions-is-deep-tms-fda-cleared-to-treat/.
4. Centers for Medicare and Medicaid Services. “LCD – Transcranial Magnetic Stimulation (TMS) in the Treatment of Adults with Major Depressive Disorder (L34998).” Novitas Solutions, Inc., revision effective December 11, 2022. Accessed August 25, 2026. https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=34998.
5. 988 Suicide and Crisis Lifeline. Operated in partnership with the Substance Abuse and Mental Health Services Administration and Vibrant Emotional Health. Accessed August 25, 2026. https://988lifeline.org/.

Learn more about Yellowbrick Consultation and Treatment Center on Google.